- Home
- ACET vs SRFM Comparison
ACET vs SRFM Comparison
Compare ACET & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- SRFM
- Stock Information
- Founded
- ACET 1947
- SRFM 2011
- Country
- ACET United States
- SRFM United States
- Employees
- ACET N/A
- SRFM N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- SRFM Transportation Services
- Sector
- ACET Health Care
- SRFM Consumer Discretionary
- Exchange
- ACET Nasdaq
- SRFM Nasdaq
- Market Cap
- ACET 70.3M
- SRFM 58.2M
- IPO Year
- ACET N/A
- SRFM 2023
- Fundamental
- Price
- ACET $0.72
- SRFM $2.57
- Analyst Decision
- ACET Buy
- SRFM Strong Buy
- Analyst Count
- ACET 6
- SRFM 3
- Target Price
- ACET $6.00
- SRFM $6.02
- AVG Volume (30 Days)
- ACET 324.2K
- SRFM 243.5K
- Earning Date
- ACET 03-06-2025
- SRFM 05-13-2025
- Dividend Yield
- ACET N/A
- SRFM N/A
- EPS Growth
- ACET N/A
- SRFM N/A
- EPS
- ACET N/A
- SRFM N/A
- Revenue
- ACET N/A
- SRFM $119,425,000.00
- Revenue This Year
- ACET N/A
- SRFM N/A
- Revenue Next Year
- ACET N/A
- SRFM $45.73
- P/E Ratio
- ACET N/A
- SRFM N/A
- Revenue Growth
- ACET N/A
- SRFM 97.38
- 52 Week Low
- ACET $0.69
- SRFM $0.90
- 52 Week High
- ACET $2.40
- SRFM $6.72
- Technical
- Relative Strength Index (RSI)
- ACET 37.26
- SRFM 33.85
- Support Level
- ACET $0.74
- SRFM $3.53
- Resistance Level
- ACET $0.91
- SRFM $3.66
- Average True Range (ATR)
- ACET 0.06
- SRFM 0.39
- MACD
- ACET -0.00
- SRFM -0.12
- Stochastic Oscillator
- ACET 12.61
- SRFM 5.41
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.